Merck (MRK) Announces KEYTRUDA Approved in Japan in Combination With Chemotherapy for First-Line Treatment of Patients With Radically Unresectable, Advanced or Recurrent Esophageal Carcinoma
Go back to Merck (MRK) Announces KEYTRUDA Approved in Japan in Combination With Chemotherapy for First-Line Treatment of Patients With Radically Unresectable, Advanced or Recurrent Esophageal Carcinoma| Merck & Co. (NYSE: MRK) | Delayed: 144.71 -2.82 (1.91%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $147.53 | 52 Week High | $65.46 | |||
| Open | $147.94 | 52 Week Low | $47.97 | |||
| Day High | $148.00 | P/E | 98.44 | |||
| Day Low | $144.10 | EPS | $1.47 | |||
| Volume | 7,547,417 | |||||
